Neuralink Wins FDA Clearance to Expand Its Brain-Implant Trial

FREMONT, Calif. — Neuralink said Friday that U.S. regulators have cleared a significant expansion of its human clinical trial, allowing the company to implant many more participants and activate additional surgical sites as it moves its brain-computer interface from a small pioneering cohort toward wider study.

The Food and Drug Administration clearance raises the number of people who can receive the company's N1 implant and adds hospital partners in several states, a step Neuralink framed as the beginning of the move from a handful of landmark cases to a repeatable medical procedure.

From First Patients to a Program

The expansion builds on a run of milestones. Neuralink participants have used the implant to control computers and robotic limbs by thought, and the company recently reported that a Blindsight patient read letters for the first time using a separate visual-prosthesis device. On the communication side, the company showed an ALS patient holding a live conversation through a speech implant.

Those results, drawn from a deliberately small group, were enough to persuade regulators that the device and the robotic surgical system that places it are ready for a larger safety and performance study. Neuralink said the broader trial will track how the implant holds up over longer periods and across a more varied group of participants.

Faster, More Standardized Surgery

Central to the case for expansion is the surgical robot Neuralink built to thread the implant's hair-thin electrode wires into the brain with a precision no human hand can match. The company has steadily shortened the procedure and says standardizing it across multiple hospitals is the key to scaling without sacrificing safety.

Each new site is trained on the same robotic workflow, which Neuralink argues will keep outcomes consistent as the number of surgeries climbs. The company is prioritizing participants with severe paralysis and other conditions that limit movement and communication, the population its devices are first designed to help.

A Wider Road Ahead

Neuralink has long said its near-term mission is restoring lost function, with a longer horizon of general human-computer symbiosis. The expanded trial keeps the focus squarely on the medical mission, generating the kind of larger data set that any eventual path to broad approval will require.

More on the company and its devices is posted at neuralink.com. Neuralink said it expects enrollment to accelerate now that more sites are coming online, and that the growing pool of participants should sharpen both the hardware and the software that turns neural signals into action.